Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAIME F AVECILLAS

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1366409245
CMS profile
857089
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$9,636.31

58 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAIME F AVECILLAS

NPI 1366409245 · CMS profile ID 857089

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366409245?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAIME F AVECILLAS, NPI 1366409245, CMS profile ID 857089. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366409245?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JAIME F AVECILLAS, NPI 1366409245, CMS profile ID 857089. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366409245?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JAIME F AVECILLAS, NPI 1366409245, CMS profile ID 857089, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1366409245?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

58 matching records · $9,636.31 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 58 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–58 of 58.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $23.2802/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944464175 CMS
Nabriva Therapeutics, plc $23.2402/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 961090909 CMS
Insmed, Inc. $15.2702/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 906438721 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.7302/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887487969 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.8501/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887487971 CMS
GlaxoSmithKline, LLC. $13.9901/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944464183 CMS
Actelion Pharmaceuticals US, Inc. $22.0001/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885380715 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,365.0001/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887487981 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $14,888.86 52
PY2020 $6,682.99 19
PY2021 $8,333.76 41
PY2022 $9,636.31 58
PY2023 $11,798.06 57
PY2024 $9,021.45 61
PY2025 $9,947.40 71

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $899,621.19 50
PY2024 Principal investigator $649,150.00 28
PY2023 Principal investigator $17,500.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $12,900.00 12/22/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128985
Principal investigator 1 SANOFI US SERVICES INC. $27,444.00 12/22/2025 Non-covered Recipient Entity
High Quality Research Inc
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226128996
Principal investigator 1 SANOFI US SERVICES INC. $16,800.00 12/08/2025 Non-covered Recipient Entity
High Quality Research Inc
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226128977
Principal investigator 1 SANOFI US SERVICES INC. $9,848.00 11/24/2025 Non-covered Recipient Entity
High Quality Research Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226128972
Principal investigator 1 SANOFI US SERVICES INC. $20,583.10 11/17/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128965
Principal investigator 1 SANOFI US SERVICES INC. $482.85 11/04/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128951
Principal investigator 1 SANOFI US SERVICES INC. $19,527.00 11/04/2025 Non-covered Recipient Entity
High Quality Research Inc
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226128961
Principal investigator 1 SANOFI US SERVICES INC. $291.79 10/14/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128933
Principal investigator 1 SANOFI US SERVICES INC. $8,274.00 10/14/2025 Non-covered Recipient Entity
High Quality Research Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226128938
Principal investigator 1 SANOFI US SERVICES INC. $12,470.00 10/06/2025 Non-covered Recipient Entity
High Quality Research Inc
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226128926
Principal investigator 1 SANOFI US SERVICES INC. $26,267.30 10/06/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128930
Principal investigator 1 SANOFI US SERVICES INC. $995.24 09/22/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128919
Principal investigator 1 SANOFI US SERVICES INC. $2,281.00 09/22/2025 Non-covered Recipient Entity
High Quality Research Inc
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226128922
Principal investigator 1 SANOFI US SERVICES INC. $12,599.00 09/15/2025 Non-covered Recipient Entity
High Quality Research Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226128895
Principal investigator 1 SANOFI US SERVICES INC. $28,423.60 09/08/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128906
Principal investigator 1 SANOFI US SERVICES INC. $12,125.00 08/18/2025 Non-covered Recipient Entity
High Quality Research Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226128868
Principal investigator 1 SANOFI US SERVICES INC. $1,334.50 08/18/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128881
Principal investigator 1 SANOFI US SERVICES INC. $23,892.00 08/11/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128873
Principal investigator 1 SANOFI US SERVICES INC. $8,000.00 08/04/2025 Non-covered Recipient Entity
High Quality Research Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226128844
Principal investigator 1 SANOFI US SERVICES INC. $5,500.00 08/04/2025 Non-covered Recipient Entity
High Quality Research Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226128864
Principal investigator 1 SANOFI US SERVICES INC. $4,178.00 07/28/2025 Non-covered Recipient Entity
High Quality Research Inc
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226128848
Principal investigator 1 SANOFI US SERVICES INC. $11,314.00 07/28/2025 Non-covered Recipient Entity
High Quality Research Inc
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226128852
Principal investigator 1 SANOFI US SERVICES INC. $13,920.00 07/21/2025 Non-covered Recipient Entity
High Quality Research Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226128829
Principal investigator 1 SANOFI US SERVICES INC. $51,423.60 07/14/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128788
Principal investigator 1 SANOFI US SERVICES INC. $750.00 07/14/2025 Non-covered Recipient Entity
High Quality Research Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226128791
Principal investigator 1 SANOFI US SERVICES INC. $787.85 07/14/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128797
Principal investigator 1 SANOFI US SERVICES INC. $18,230.00 07/14/2025 Non-covered Recipient Entity
High Quality Research Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226128801
Principal investigator 1 SANOFI US SERVICES INC. $540.00 07/14/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128805
Principal investigator 1 SANOFI US SERVICES INC. $1,760.00 07/14/2025 Non-covered Recipient Entity
High Quality Research Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226128813
Principal investigator 1 SANOFI US SERVICES INC. $4,790.00 07/02/2025 Non-covered Recipient Entity
High Quality Research Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226128817
Principal investigator 1 SANOFI US SERVICES INC. $1,560.00 06/16/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128772
Principal investigator 1 SANOFI US SERVICES INC. $2,200.00 06/16/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128775
Principal investigator 1 SANOFI US SERVICES INC. $17,229.00 06/09/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226128760
Principal investigator 1 SANOFI US SERVICES INC. $44,824.00 06/09/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128764
Principal investigator 1 SANOFI US SERVICES INC. $33,859.40 05/12/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128751
Principal investigator 1 SANOFI US SERVICES INC. $5,900.00 05/05/2025 Non-covered Recipient Entity
High Quality Research Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226128724
Principal investigator 1 SANOFI US SERVICES INC. $39,177.00 04/28/2025 Non-covered Recipient Entity
High Quality Research Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226128727
Principal investigator 1 SANOFI US SERVICES INC. $3,060.16 04/14/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128736
Principal investigator 1 SANOFI US SERVICES INC. $19,180.00 04/07/2025 Non-covered Recipient Entity
High Quality Research Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226128674
Principal investigator 1 SANOFI US SERVICES INC. $60,464.50 04/07/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128706
Principal investigator 1 SANOFI US SERVICES INC. $39,098.00 04/02/2025 Non-covered Recipient Entity
High Quality Research Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226128666
Principal investigator 1 SANOFI US SERVICES INC. $17,700.00 03/17/2025 Non-covered Recipient Entity
High Quality Research Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226128644
Principal investigator 1 SANOFI US SERVICES INC. $56,386.90 03/17/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128698
Principal investigator 1 SANOFI US SERVICES INC. $15,692.00 03/10/2025 Non-covered Recipient Entity
High Quality Research Inc
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226128687
Principal investigator 1 SANOFI US SERVICES INC. $15,039.00 03/04/2025 Non-covered Recipient Entity
High Quality Research Inc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226128625
Principal investigator 1 SANOFI US SERVICES INC. $25,020.00 02/18/2025 Non-covered Recipient Entity
High Quality Research Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226128651
Principal investigator 1 SANOFI US SERVICES INC. $40,950.00 02/18/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128693
Principal investigator 1 SANOFI US SERVICES INC. $77,699.40 02/18/2025 Non-covered Recipient Entity
High Quality Research Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226128709
Principal investigator 1 SANOFI US SERVICES INC. $910.00 02/10/2025 Non-covered Recipient Entity
High Quality Research Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226128629
Principal investigator 1 SANOFI US SERVICES INC. $25,940.00 01/21/2025 Non-covered Recipient Entity
High Quality Research Inc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226128639